All In Biotech

Free tool

FAERS Monitor: Azulfidine En-Tabs

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021243 or its brand name (Azulfidine En-Tabs, Sulfasalazine). Reports on generic versions are filed under their own applications.

Reports

78,454

Serious

65,745

84% of reports

Hospitalization

21,747

Death reported

7,496

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • drug ineffective29,490
  • rheumatoid arthritis19,666
  • pain16,091
  • drug intolerance13,852
  • arthralgia13,600
  • fatigue13,447
  • joint swelling12,846
  • off label use11,276
  • rash11,118
  • abdominal discomfort10,166
  • contraindicated product administered9,780
  • condition aggravated9,702
  • alopecia9,553
  • synovitis9,347
  • arthropathy9,286

Reports by year received

View as table
YearReports
2004636
2005614
2006684
2007832
2008843
2009829
2010870
20111,147
20121,441
20131,324
20141,510
20152,401
20163,318
20175,227
20186,253
20197,389
202011,228
20217,186
20227,151
20235,138
20245,753
20254,579
20262,100

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,975,705 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
synovitisSignal9,347287.1279.11,286,069
contraindicated product administeredSignal9,780127.4124.5831,681
rheumatoid arthritisSignal19,66655.955.2882,360
arthropathySignal9,28653.652.4400,002
drug intoleranceSignal13,85244.744.0509,350
joint swellingSignal12,84631.831.3344,486
abdominal discomfortSignal10,16617.216.9147,163
alopeciaSignal9,55313.713.4107,599
arthralgiaSignal13,6009.08.995,848
condition aggravatedSignal9,7028.88.665,918
painSignal16,0917.27.185,926
rashSignal11,1187.06.956,792
drug ineffectiveSignal29,4906.16.1131,540
fatigueSignal13,4474.74.639,892
off label useSignal11,2763.53.420,570

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.